Chiome Bioscience Inc.
TTSE:458391.00
JPY
-3.00
(-3.19%)
ISIN
JP3205350006
Return %
Stock
S&P 500
1Y
-33.09
14.20
3Y
-27.78
81.12
5Y
-61.76
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Masamichi Koike
- Full Time Employees
- 49
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Sumitomo Fudosan Nishi-shinjuku Bldg.No.6 Tokyo TY Japan 151-0071
- IPO Date
- Dec 2, 2011
- Website
- chiome.co.jp
- Similar Companies
- Business
- Chiome Bioscience Inc. is actively engaged in the exploration and advancement of innovative drug discovery platforms around the globe. The company structures its operations into two primary divisions: its core Drug Development endeavors and its specialized Drug Discovery Support services. Central to its offerings is the ADLib System, a proprietary platform for generating monoclonal antibodies essential for therapeutic development, alongside the Human ADLib System, which facilitates the conversion of chicken-derived antibody genes into humanized forms. The firm also delivers expertise in protein production and purification, services for creating stable cell lines tailored for recombinant protein and antibody manufacturing, and custom antibody generation through its ADLib system or established B cell cloning techniques. Further enhancing its capabilities, Chiome has introduced the DoppeLib system for the high-throughput screening of bispecific antibodies. The company's therapeutic pipeline features several key assets. CBA-1205, an anti-DLK1 monoclonal antibody, is currently progressing through Phase I clinical trials for advanced solid tumors, including hepatocellular carcinoma, melanoma, and pediatric cancers, with observed partial responses in hepatocellular carcinoma and long-term stable disease in melanoma patients. Similarly, CBA-1535, a T-cell engager targeting 5T4/CD3, is also under Phase I investigation for advanced solid tumors, showing early indications of T-cell activation without significant safety concerns. Recently, PFKR, a humanized anti-CX3CR1 antibody in the preclinical stage aimed at inflammatory and neurological disorders, entered into an exclusive global licensing agreement with Asahi Kasei Pharma, including an upfront payment and potential milestone and royalty earnings. Licensing discussions are also underway for PCDC. Further preclinical assets include LIV-2008/2008b, an anti-TROP-2 antibody for various cancers; BMAA, an anti-semaphorin3a antibody for central, immune/inflammatory, neurological, and ophthalmic conditions; and PTRY, an antibody targeting 5T4/CD3/PD-L1 for multiple solid tumors. Chiome Bioscience maintains a strategic focus on expanding its Integrated Drug Discovery (IDD) business, leveraging its antibody discovery platform. This includes a recent collaboration with OmniAb for advanced bispecific antibody screening. Additionally, the company is involved in establishing Japan's first end-to-end biosimilar supply chain through a joint venture with Kidswell Bio and Mycenax, supported by Alfresa Holdings. Its client base spans universities, research institutions, and pharmaceutical enterprises. Established in 2005, Chiome Bioscience Inc. is headquartered in Tokyo, Japan.